文献速递前列腺癌

放射性同位素引导的淋巴结清扫术用于中危和高危前列腺癌患者盆腔淋巴结分期(前瞻性SENTINELLE研究)

Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
PubMed 文献 · J Urol · 2022-11-04

这项在法国3个三级中心开展的前瞻性单臂多中心研究,于2012年2月至2019年5月纳入162例临床局限期中危或高危前列腺癌患者,评估前哨淋巴结活检引导的淋巴结清扫术以扩大盆腔淋巴结清扫术为参考标准的诊断准确性;前哨淋巴结活检法检测至少1枚淋巴结转移的敏感性为95.4%,特异性为100%。

要点

  • 162例cN0M0患者中,中危106例(65.4%),高危56例(34.6%)。
  • 每例患者获取淋巴结数中位14枚(均值16,IQR 10-21)。
  • 最终病理分析中22例(13.6%)为pN+。

核心结论

  • 这项多中心前瞻性研究支持前哨淋巴结活检是局限期中危或高危前列腺癌患者盆腔淋巴结分期中非常有效且敏感的方法。

研究设计与样本

  • 前瞻性、单臂、多中心研究,在法国3个三级中心于2012年2月至2019年5月开展,纳入临床局限期中危或高危前列腺癌患者。
  • 经前列腺内注射(99m)Tc-纳米胶体后,术前淋巴显像定位前哨淋巴结,术中伽马探头引导切除前哨淋巴结,随后所有患者均行扩大盆腔淋巴结清扫术。
  • 以扩大盆腔淋巴结清扫术为参考标准评估前哨淋巴结活检法的诊断准确性,试验注册于ClinicalTrials.gov(NCT02732392)。

主要发现

  • 共纳入162例cN0M0(CT扫描和骨扫描)男性患者,中危106例(65.4%),高危56例(34.6%)。
  • 每例患者获取淋巴结数中位14枚(均值16,IQR 10-21)。
  • 最终病理分析中22例(13.6%)为pN+。
  • 前哨淋巴结活检法检测至少1枚淋巴结转移患者的敏感性95.4%(95%CI 75.1-99.7),特异性100%(95%CI 96.6-100),阴性预测值99.2%(95%CI 95.5-99.9),阳性预测值100%(95%CI 80.7-100)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our aim was to prospectively evaluate the diagnostic accuracy of sentinel lymph node biopsy-guided lymph node dissection compared to extended pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer. MATERIALS AND METHODS: We conducted a prospective, single-arm, multicenter study at 3 tertiary centers in France between February 2012 and May 2019. Eligible patients had clinically localized intermediate- or high-risk prostate cancer. After intraprostatic injection of (99m)Tc-nanocolloid, the locations of the sentinel lymph nodes were defined by preoperative lymphoscintigraphy. Surgical excision of the sentinel lymph nodes was performed using intraoperative gamma probe guidance. After resection of the sentinel lymph nodes, extended pelvic lymph node dissection was performed in all patients. We assessed the diagnostic accuracy of the sentinel lymph node biopsy method using extended pelvic lymph node dissection as the reference standard. This trial was registered in ClinicalTrials.gov (NCT02732392). RESULTS: A total of 162 men cN0M0 (CT scan and bone scan) were enrolled: 106 (65.4%) and 56 (34.6%) patients had intermediate- and high-risk prostate cancer, respectively. The median number of nodes retrieved was 14 (mean 16, IQR 10-21) per patient. At final pathological analysis, 22 patients (13.6%) were pN+. Sensitivity, specificity, negative predictive value, and positive predictive value of sentinel lymph node biopsy method in detecting patients with at least 1 lymph node metastasis were 95.4% (95% CI, 75.1-99.7), 100% (95% CI, 96.6-100), 99.2% (95% CI, 95.5-99.9), and 100% (95% CI, 80.7-100), respectively. CONCLUSIONS: Our multicenter prospective study supports that sentinel lymph node biopsy is a very effective and sensitive method for pelvic lymph node staging in patients with intermediate- or high-risk localized prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lannes F, Baboudjian M, Ruffion A, et al. Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study). J Urol. 2022. PMID: 36331157. doi:10.1097/JU.0000000000003043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。